[go: up one dir, main page]

WO2018151938A3 - Compositions and methods of determining a level of infection in a subject - Google Patents

Compositions and methods of determining a level of infection in a subject Download PDF

Info

Publication number
WO2018151938A3
WO2018151938A3 PCT/US2018/016115 US2018016115W WO2018151938A3 WO 2018151938 A3 WO2018151938 A3 WO 2018151938A3 US 2018016115 W US2018016115 W US 2018016115W WO 2018151938 A3 WO2018151938 A3 WO 2018151938A3
Authority
WO
WIPO (PCT)
Prior art keywords
infection
methods
level
compositions
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/016115
Other languages
French (fr)
Other versions
WO2018151938A2 (en
Inventor
Ye Hu
Chang Liu
Xin Ma
Yaojun LI
Steven Michael HOLLAND
Zhen Zhao
Adrian Zelazny
Christopher John Lyon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methodist Hospital
Original Assignee
Methodist Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methodist Hospital filed Critical Methodist Hospital
Publication of WO2018151938A2 publication Critical patent/WO2018151938A2/en
Publication of WO2018151938A3 publication Critical patent/WO2018151938A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Nanotechnology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

Provided herein are nanoparticles configured for the rapid detection of disease-specific peptides from patient samples, including blood-based samples. Also provided are methods of measuring the level of an infection by isolation and quantification of disease-specific peptides from patient samples. The nanoparticles may act as a co-matrix for matrix assisted laser desorption/ionization mass spectrometry.
PCT/US2018/016115 2017-02-17 2018-01-31 Compositions and methods of determining a level of infection in a subject Ceased WO2018151938A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762460280P 2017-02-17 2017-02-17
US62/460,280 2017-02-17
US201762597775P 2017-12-12 2017-12-12
US62/597,775 2017-12-12

Publications (2)

Publication Number Publication Date
WO2018151938A2 WO2018151938A2 (en) 2018-08-23
WO2018151938A3 true WO2018151938A3 (en) 2018-10-11

Family

ID=63170421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/016115 Ceased WO2018151938A2 (en) 2017-02-17 2018-01-31 Compositions and methods of determining a level of infection in a subject

Country Status (1)

Country Link
WO (1) WO2018151938A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210106742A1 (en) * 2019-10-14 2021-04-15 Actorius Innovations And Research Co Non-hemolytic compositions and methods of use for recovering disease causing toxic constituents in the blood
WO2022032184A1 (en) 2020-08-05 2022-02-10 The Administrators Of The Tulane Educational Fund Method of detecting tb in bodily fluid samples

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054407A1 (en) * 2005-07-21 2007-03-08 Academia Sinica Mass spectrometric analysis of ligand conjugated magnetic nanoparticles
US20100240088A1 (en) * 2007-01-12 2010-09-23 Erasmus University Medical Center Rotterdam Peptide Markers for Diagnosis of Angiogenesis
US20110236411A1 (en) * 2007-09-27 2011-09-29 Dako Denmark A/S MHC Multimers in Tuberculosis Diagnostics, Vaccine and Therapeutics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054407A1 (en) * 2005-07-21 2007-03-08 Academia Sinica Mass spectrometric analysis of ligand conjugated magnetic nanoparticles
US20100240088A1 (en) * 2007-01-12 2010-09-23 Erasmus University Medical Center Rotterdam Peptide Markers for Diagnosis of Angiogenesis
US20110236411A1 (en) * 2007-09-27 2011-09-29 Dako Denmark A/S MHC Multimers in Tuberculosis Diagnostics, Vaccine and Therapeutics

Also Published As

Publication number Publication date
WO2018151938A2 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
WO2018072862A8 (en) Method for evaluating data from mass spectrometry, mass spectrometry method, and maldi-tof mass spectrometer
GB2556994A (en) Tissue analysis by mass spectrometry or ion mobility spectrometry
WO2020047010A8 (en) Increasing spatial array resolution
EP3570315A3 (en) Rapid evaporative ionisation mass spectrometry ("reims") and desorption electrospray ionisation mass spectrometry ("desi-ms") analysis of biopsy samples
WO2018026591A3 (en) Systems and methods for integrating ion mobility and ion trap mass spectrometers
WO2014146139A3 (en) Srm assay to indicate cancer therapy
HK1220472A1 (en) Neuroactive steroids, compositions, and uses thereof
EP3741303A3 (en) Chemically guided ambient ionisation mass spectrometry
WO2014164026A3 (en) Preparation enhancements and methods of use for maldi mass spectrometry
WO2012085594A3 (en) Improved space focus time of flight mass spectrometer
WO2017027611A3 (en) Biomarkers of methylglyoxal and related methods thereof
EP2819148A3 (en) Electron ionization (EI) utilizing different EI energies
EP2343546A3 (en) Ion mobility spectrometer
WO2021110799A3 (en) Methods and device for the analysis of tissue samples
WO2014179424A3 (en) Lipidomic biomarkers
WO2016196993A8 (en) Multi-mediator reagent formulations for use in electrochemical detection
PH12019550236A1 (en) Detection of misfolded tau protein
JP2017525971A5 (en)
EP2423945A3 (en) Drug detection equipment
WO2017083729A3 (en) Fixatives and methods of use
EP3438277A4 (en) Method for determining whether or not test sample contains phytopathogenic fungus
EP3745123C0 (en) MASS SPECTROMETRIC SYSTEM WITH ION MOBILITY ANALYSIS AT Elevated Pressure
EP4141909A3 (en) Dynamic range enhancement
WO2018151938A3 (en) Compositions and methods of determining a level of infection in a subject
WO2013184995A8 (en) Methods and apparatus for performing mass spectrometry

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18754974

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18754974

Country of ref document: EP

Kind code of ref document: A2